Aurora Cannabis Inc.
NASDAQ:ACBDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $289.28M
- Beta
- 1.34
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$1.31
Volume 0.92M
Average 1.00M
ACB Net Income
Bottom-line profit after all expenses, interest, and taxes.
Aurora Cannabis Inc.NASDAQ: ACB
Net Income · Q4 FY2026 · quarter ended Mar 2026
Net income remains negative
Q4 FY2026 net income was -CA$57.04M, compared with -CA$24.56M a year earlier. Trailing-twelve-month net income was -CA$75.03M.
Context
- Net income amounted to 38.0% of revenue in FY2026, up 37.5 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -CA$26.79M (+78.1%) for the fiscal year ending Mar 2027, a step up from the -7772.8% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CA$57.04M-3234.3% QoQ
- Last fiscal yearMar 2026
- -CA$122.07M-7772.8% YoY
- LTMMar 2026
- -CA$75.03M-4815.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -132.3% | -138.3% | -6.0 pp |
| 1 year | -7772.8% | +78.1% | +7850.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
CAD · from the income statement
- Latest · FY2026
- (122.07M) CAD
- Year-over-year change
- -7772.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | (122.07M) | -7772.8% |
| FY2025 | 2025-03-31 | 1.59M | +102.3% |
| FY2024 | 2024-03-31 | (69.33M) | +91.5% |
| FY2023 | 2023-03-31 | (816.63M) | +52.5% |
| FY2022 | 2022-06-30 | (1.72B) | — |
Net Income vs competitors
How ACB compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -4815.8% is the lowest of 10, against a peer median of +26.3%.
- Net income amounts to 24.1% of revenue for ACB, versus a peer median of 34.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $102.18M USD | +415.9% | -48.4% | 28.3% | |
| LTM Mar 2026 | -$16.25M USD | -58.5% | — | 7.4% | |
| LTM Mar 2026 | -$17.17M USD | +26.3% | — | 41.1% | |
| LTM Mar 2026 | -CA$25.23M CAD | -249.4% | — | 9.2% | |
| LTM Mar 2026 | -$34.09M USD | — | — | 25.2% | |
| LTM Apr 2026 | -CA$44.03M CAD | -355.0% | — | 6.6% | |
| LTM Mar 2026 | -$69.66M USD | +46.5% | — | 832.6% | |
| LTM Mar 2026 | -CA$75.03M CAD | -4815.8% | — | 24.1% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.93M USD | -26.6% | — | 871.8% |
| LTM Mar 2026 | -$108.95M USD | +56.6% | — | 281.6% | |
| LTM Mar 2026 | -CA$366.64M CAD | +38.7% | — | 117.4% | |
| Peer median (excluding ACB) | — | +26.3% | -48.4% | 34.7% | |
Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 221.34M | 223.8M | 270.28M | 343.29M | 321.42M |
| Cost of Revenue | 200.11M | 209.02M | 138.82M | 155.69M | 304.67M |
| Gross Profit | 21.23M | 14.78M | 131.46M | 187.61M | 16.75M |
| Gross Margin | 9.6% | 6.6% | 48.6% | 54.6% | 5.2% |
| Research & Development | 10.39M | 5.77M | 3.57M | 3.68M | 6.01M |
| Selling, General & Admin | 188.99M | 170.48M | 156.88M | 166.47M | 173.95M |
| Operating Expenses | 252.67M | 221.98M | 177.91M | 182.66M | 179.96M |
| Depreciation & Amortization | 93.66M | 52.59M | 33.07M | 22.55M | 14.23M |
| EBITDA | (1.55B) | (135M) | (12.34M) | 51.35M | (148.99M) |
| EBITDA Margin | -702.4% | -60.3% | -4.6% | 15.0% | -46.4% |
| Operating Income | (231.45M) | (207.19M) | (46.45M) | 4.95M | (163.21M) |
| Operating Margin | -104.6% | -92.6% | -17.2% | 1.4% | -50.8% |
| Interest Income | 4.51M | 19M | 12.81M | 11.51M | 5.86M |
| Interest Expense | 71.81M | 39.46M | 14.19M | 8.42M | 1.81M |
| Other Income / Expenses | (1.49B) | (576.51M) | (13.15M) | 15.43M | 106.54M |
| Income Before Tax | (1.72B) | (783.7M) | (59.6M) | 20.38M | (56.67M) |
| Pre-Tax Margin | -777.1% | -350.2% | -22.1% | 5.9% | -17.6% |
| Income Tax Expense | (2.14M) | 16.55M | (554K) | 4.62M | 2.1M |
| Net Income | (1.72B) | (816.63M) | (69.33M) | 1.59M | (122.07M) |
| Net Margin | -776.0% | -364.9% | -25.6% | 0.5% | -38.0% |
| EPS (Basic) | (79.92) | (8.17) | (1.28) | 0.03 | (2.15) |
| EPS (Diluted) | (79.92) | (8.17) | (1.28) | 0.03 | (2.15) |
| Weighted Avg Shares | 21.49M | 32.27M | 51.26M | 54.88M | 56.71M |
| Weighted Avg Shares (Diluted) | 21.49M | 32.27M | 51.26M | 55.75M | 56.71M |
Aurora Cannabis Inc.
NASDAQ:ACB
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.